Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: The ALLHAT-LLT randomized clinical trial

JAMA Internal Medicine

Volumn 177, Issue 7, 2017, Pages 955-965

  Han, Benjamin H ^a   Sutin, David ^a   Williamson, Jeff D ^b   Davis, Barry R ^c   Piller, Linda B ^c   Pervin, Hannah ^c   Pressel, Sara L ^c   Blaum, Caroline S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG DOSE INCREASE; FATALITY; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT CARE; POST HOC ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CARDIOVASCULAR DISEASES; CONTROLLED STUDY; DRUG MONITORING; EPIDEMIOLOGY; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT; MORTALITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG MONITORING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MEDICATION THERAPY MANAGEMENT; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRAVASTATIN; PRIMARY PREVENTION; UNITED STATES;

EID: 85021307572     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.1442     Document Type: Article

References (37)

1. United States Census Bureau. 2012 National population projections: summary tables. http://www.census.gov/population/projections/data/national/2012/summarytables.html. Accessed April 10, 2017.
2. Chokshi NP,Messerli FH, Sutin D, Supariwala AA, Shah NR. Appropriateness of statins in patients aged-80 years and comparison to other age groups. Am J Cardiol. 2012;110(10):1477-1481.
3. Johansen ME, Green LA. Statin use in very elderly individuals, 1999-2012. JAMA Intern Med. 2015;175(10):1715-1716.
4. Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA. 2014;312(11):1136-1144.
5. Weinberger Y, Han BH. Statin treatment for older adults: the impact of the 2013 ACC/AHA cholesterol guidelines. Drugs Aging. 2015;32(2):87-93.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
7. de Ruijter W,Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009;338:a3083.
8. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272(17):1335-1340.
9. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 2001;358(9279):351-355.
10. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med. 1993;153(9):1065-1073.
11. Petersen LK, Christensen K, Kragstrup J. Lipidlowering treatment to the end? a review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing. 2010;39(6):674-680.
12. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25, pt B):2889-2934.
13. Han BH,Weinberger Y, Sutin D. Statinopause. J Gen Intern Med. 2014;29(12):1702-1706.
14. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997-2007.
15. Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA Intern Med. 2017;177(1):21-23.
16. Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
17. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488-496, W174.
18. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021-2031.
19. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER Study Group (Prospective Study of Pravastatin in the Elderly at Risk). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
20. Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med. 2015;162 (8):533-541.
21. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
22. Davis BR, Cutler JA, Gordon DJ, et al; ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).AmJ Hypertens. 1996;9(4, pt 1):342-360.
23. Pressel S, Davis BR, Louis GT, et al; ALLHAT Research Group. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials. 2001;22(6):674-686.
24. Wright JT Jr, Cushman WC, Davis BR, et al; ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. Control Clin Trials. 2001;22(6):659-673.
25. ALLHAT. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Data Coordinating Center. http://allhat.org. Accessed November 1, 2016.
26. Wenger NS, Shekelle PG. Assessing Care of Vulnerable Elders: ACOVE project overview. Ann Intern Med. 2001;135(8, pt 2):642-646.
27. Wenger NS, Roth CP, Shekelle P; ACOVE Investigators. Introduction to the Assessing Care of Vulnerable Elders-3 quality indicator measurement set. J AmGeriatr Soc. 2007;55(suppl 2):S247-S252.
28. Sewright KA, Clarkson PM, Thompson PD. Statinmyopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9(5): 389-396.
29. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172(15):1180-1182.
30. Padala KP, Padala PR, Potter JF. Statins: a case for drug withdrawal in patients with dementia. J Am Geriatr Soc. 2010;58(6):1214-1216.
31. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059): 2532-2561.
32. Krumholz HM. Statins evidence: when answers also raise questions. BMJ. 2016;354:i4963.
33. Alpérovitch A, Kurth T, Bertrand M, et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ. 2015;350:h2335.
34. Jacobs JM, Cohen A, Ein-Mor E, Stessman J. Cholesterol, statins, and longevity from age 70 to 90 years. J AmMed Dir Assoc. 2013;14(12):883-888.
35. Gnjidic D, Le Couteur DG, Blyth FM, et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open. 2013;3(3):e002333.
36. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J AmColl Cardiol. 2008;51(1):37-45.
37. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170(12):1032-1036.